Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

Neuro-Oncology

Volumn 17, Issue 11, 2015, Pages 1504-1513

  Field, Kathryn M ^a   Simes, John ^b,k   Nowak, Anna K ^c,d   Cher, Lawrence ^e,p   Wheeler, Helen ^f   Hovey, Elizabeth J ^g,h   Brown, Christopher S B ^b   Barnes, Elizabeth H ^b   Sawkins, Kate ^b   Livingstone, Ann ^b   Freilich, Ron ⁱ   Phal, Pramit M ^a,j   Fitt, Greg ^e,j   Rosenthal, Mark A ^a,j   Arzhintar, I ⁱ   Garrett, L ^a   Byrne, A ^k   Dowling, A ^l   Ranieri, N ^l   Jennens, R ^m   Osmond, F ^m   Patterson, W K ⁿ   Phay, A ⁿ   Abell, F ^o   Plowman, L ^o   Flynn, J ^p   Hovey, E ^g,h   Kilsby, H ^g   Wheeler, H ^f   Kirby Lewis, S ^f   Singhal, N ^q   Smith, S ^q   Whelan, M ^q   Inglis, P ^r   Ives, A ^r   Lobb, S ^c   Begbie, S ^s   Williams, P ^s   Lwin, Z ^t   Woodward, N ^t   Crosbie, G ^t   Harrup, R ^u   Pyszkowski, L ^u   Gauden, S ^v   Neville, A ^v   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e AUSTIN HEALTH   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ MONASH MEDICAL CENTRE   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l ST VINCENT S HOSPITAL   (Australia)

^m EPWORTH HEALTHCARE   (Australia)

ⁿ Queen Elizabeth Hospital   (United Kingdom)

^o CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^p AUSTIN HOSPITAL   (Australia)

^q ROYAL ADELAIDE HOSPITAL   (Australia)

^r ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^s PORT MACQUARIE BASE HOSPITAL   (Australia)

^t MATER ADULT HOSPITAL   (Australia)

^u ROYAL HOBART HOSPITAL   (Australia)

^v LAUNCESTON GENERAL HOSPITAL   (Australia)

more..

Author keywords

bevacizumab; carboplatin; glioblastoma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ANTINEOPLASTIC AGENT;

ABSCESS; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; AUSTRALIA; BLEEDING; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS;

EID: 84946566977     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov104     Document Type: Article

References (29)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
2. Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9): 494-503; quiz 491 p following 516.
3. Australian Cancer Network Adult Brain Tumour Guidelines Working Party, Clinical Practice Guidelines for the Management of Adult Gliomas: Astrocytomas and Oligodendrogliomas. Sydney: Cancer Council Australia, Australian Cancer Network and Clinical Oncological Society of Australia Inc., 2009.
4. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578.
5. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000;26(6): 397-409.
6. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26): 3212-3218.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
9. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-1138.
10. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
11. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep. 2011;13(1):50-56.
12. Henriksson R, Bottomley A, Mason W, et al. Progression-free survival (PFS) and health-related quality of life (HRQo L) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma [abstract2 2005]. J Clin Oncol. 2013;31(Suppl).
13. Armstrong T, Won M, Wefel J, et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract 2003]. J Clin Oncol. 2013;31(Suppl).
14. Wefel J, Pugh S, Armstrong T, et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract 2004]. J Clin Oncol. 2013;31(Suppl).
15. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991; 9(5):860-864.
16. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994;19(1):69-74.
17. Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012;107(1):155-164.
18. Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci. 2010;17(8):970-974.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events version 4.0. Available from: http://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm - ctc-40 Accessed July 2014.
20. Thompson EM, Dosa E, Kraemer DF, et al. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010;67(1):87-93.
21. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
22. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
23. Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118(5): 1302-1312.
24. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-953.
25. Mrugala MM, Crew LK, Fink JR, et al. Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett. 2012;4(5):1082-1086.
26. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1): 173-180.
27. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010; 116(22):5297-5305.
28. Anderson MD, Hamza MA, Hess KR, et al. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014;16(6):823-828.
29. Piccioni DE, Lai A. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014;16(10):1427-1428.